Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,057.02 5.99 (0.57%) as of 4:30 Mon 7/1


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.66(B)
Last Volume: 383,195 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 2430
  Page 59 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Shooter Eric M Director   –       •      –    2014-02-12 4 OE $33.42 $1,341,750 D/D 15,000 15,000     -
   Stahl Neil SVP Research and Development S   •       –      –    2014-02-12 4 D $324.44 $10,361,316 D/D (31,936) 47,003     -
   Stahl Neil SVP Research and Development S   •       –      –    2014-02-12 4 OE $16.80 $1,094,406 D/D 54,548 50,807     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-02-12 4 AS $317.82 $28,504,985 D/D (88,987) 1,068,343     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-02-11 4 D $314.31 $31,580,612 D/D (100,476) 1,157,330     -
   Yancopoulos George President Regeneron Laboratori   •       •      –    2014-02-11 4 OE $9.49 $1,798,004 D/D 189,463 1,257,806     -
   Gilman Alfred G Director   –       •      –    2014-02-11 4 AS $320.00 $1,600,000 D/D (5,000) 0     -
   Gilman Alfred G Director   –       •      –    2014-02-11 4 OE $18.61 $93,050 D/D 5,000 5,000     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-02-11 4 AS $325.00 $1,891,175 D/D (5,819) 0     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-02-11 4 OE $30.63 $178,236 D/D 5,819 5,819     -
   Vagelos P Roy Chairman of the Board   •       •      –    2014-02-11 4 AS $325.10 $3,730,523 I/I (11,475) 103,275     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-07 4 B $284.49 $6,317,455 I/I 21,986 16,749,620 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-06 4 B $282.84 $42,008,390 I/I 146,525 16,727,634 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-05 4 B $274.64 $58,367,107 I/I 206,978 16,581,109 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-04 4 B $282.05 $54,504,789 I/I 190,286 16,374,131 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-03 4 B $279.14 $56,141,719 I/I 198,058 16,183,845 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-01-31 4 B $286.13 $3,161,383 I/I 10,914 15,985,787 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-01-28 4 B $273.44 $23,184,321 I/I 83,235 15,974,873 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-01-27 4 B $269.77 $20,386,044 I/I 74,685 15,891,638 1.5     -
   Mccorkle Douglas S VP Controller and Asst Treasur   •       –      –    2014-01-14 4 AS $290.00 $1,160,000 D/D (4,000) 0     -
   Gilman Alfred G Director   –       •      –    2014-01-14 4 AS $300.00 $1,500,000 D/D (5,000) 0     -
   Gilman Alfred G Director   –       •      –    2014-01-14 4 OE $18.61 $93,050 D/D 5,000 5,000     -
   Vagelos P Roy Chairman of the Board   •       •      –    2014-01-10 4 GD $0.00 $0 I/I 764 157,824     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2014-01-02 4 AS $272.88 $5,678,965 D/D (20,668) 25,447     -
   Powchik Peter SVP Clinical Development & Reg   •       –      –    2013-12-31 4 D $276.09 $7,546,092 D/D (27,332) 46,115     -
  2430 Records found
  Previous  50  51  52  53  54  55  56  57  58  59  Next   
  Page 59 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us